Has Mark Mehle, MD received payments from drug or device companies?

Yes. Drug and device makers reported $402,858 in general payments to Mark Mehle, MD across 452 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Mehle, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Mehle, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Mehle, MD

Otolaryngology · Cleveland, OHNPI 1760574982

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $347,114 of the $402,858 with a category attached, or 86.2%. 20 manufacturers reported payments, led by Optinose US, Inc. at 53.5% of the total. 2025 is the largest year on record at $128,626, 3.1 times the $41,107 reported in 2019. Among otolaryngology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$402,858in general payments, 2019–2025

Across 452 payments — averaging $891.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Optinose US, Inc.$216K
GSK$157K
Sanofi$11K
Regeneron Healthcare Solutions, Inc.$7K
AstraZeneca$4K
Aerin Medical Inc.$3K
plus $5K from 14 others

$5,100in research payments, 2019–2025

Across 8 payments — averaging $637.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Aerin Medical Inc.$5K

What the payments were for

Consulting fees$26,8457%
Speaking & faculty fees$347,11486%
Travel & lodging$20,7055%
Food & beverage$8,1402%
Education$550%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Optinose US, Inc.	226	$215,549
GSK	147	$157,116
Sanofi	21	$10,894
Regeneron Healthcare Solutions, Inc.	9	$7,118
AstraZeneca	8	$3,675
Aerin Medical Inc.	8	$3,099
Genentech USA, Inc.	1	$2,125
Alk-abello, Inc	4	$1,415
Pfizer	3	$1,108
Stryker	7	$329
Intersect ENT, Inc.	3	$83
Biohaven Pharmaceuticals, Inc.	3	$66
Integra Lifesciences Corporation	2	$65
Precigen, Inc.	1	$47
Medtronic	2	$46
Inspire Medical Systems, Inc.	2	$39
Novartis	2	$38
Merck	1	$16
Smith+Nephew	1	$16
Johnson & Johnson	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Xhance$212,845
NUCALA$155,153
DUPIXENT$17,576
TEZSPIRE$3,090
RHINAER STYLUS$2,800
XOLAIR$2,125
Odactra$1,339
NURTEC ODT$1,080
ENTELLUS - ENTELLUS MEDICAL REINFORCED ANESTHESIA NEEDLE$128
ENTELLUS - MINIFESS TURBINATE FORCEPS$128
ENTELLUS - XPRESS ENT DILATION SYSTEM$128
ENTELLUS - FOCESS HD WIRELESS CAMERA$128

How this compares

$402,858 in reported general payments places this provider in the 95th percentile of 380 otolaryngology providers in Ohio.

See all otolaryngology providers in Ohio →

Medicare billing

Part B allowed, 2024

$132,391

Medicare patients

602

Services billed

1,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluticasone Propionate	785	$10,445
Ipratropium Bromide	182	$5,002
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth	40	$4,530
Azelastine Hcl	158	$4,428
Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid	27	$1,941
Ofloxacin	20	$775
Mometasone Furoate	15	$751
Pantoprazole Sodium	109	$609
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	39	$380
Famotidine	20	$323
Montelukast Sodium	34	$211
Mupirocin	35	$123
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid	18	$115
Doxycycline Hyclate	12	$87
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	18	$53

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Cleveland

Raj SindwaniCleveland$598K
Troy WoodardCleveland$392K
Sanjeet RangarajanCleveland$113K
Rod RezaeeCleveland$54K
Michael BenningerCleveland$32K
Cameron WickCleveland$21K
Kyra OsborneCleveland$14K
Daniel AlamCleveland$11K
Mohamad ChaabanCleveland$10K
Kenneth RodriguezCleveland$8K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →